Open AccessA Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
Author(s) -
Melanie B. Thomas,
Elizabeth GarrettMayer,
Munazza Anis,
Kate Anderton,
Tricia Bentz,
Andie Edwards,
Alan Brisendine,
Geoffrey R. Weiss,
Abby B. Siegel,
Johanna C. Bendell,
Ari David Baron,
Vinay Duddalwar,
Anthony B. El-Khoueiry
Publication year - 2018
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000485384
Subject(s) - medicine , tolerability , hepatocellular carcinoma , sorafenib , hazard ratio , bevacizumab , gastroenterology , erlotinib , clinical endpoint , cirrhosis , discontinuation , surgery , adverse effect , randomized controlled trial , confidence interval , cancer , chemotherapy , epidermal growth factor receptor
To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC).